Skip to main content
Premium Trial:

Request an Annual Quote

Affy, Caliper, Luminex Added Back to Nasdaq Biotech Index

NEW YORK (GenomeWeb News) - The Nasdaq exchange said on Friday that it has reinstated several genomics companies that it dropped from the Nasdaq Biotechnology Index in May.
 
Affymetrix, Caliper, and Luminex are among five firms added to the index following an interim review. Nasdaq said in a statement that the "sole purpose" of the review was "to include some companies that were removed from the Index during the May semi-annual re-ranking due to sector classification assigned by the Industry Classification Benchmark."
 
In May, Accelrys, Affymetrix, Caliper Life Sciences, and Luminex were among nine firms dropped from the index due to a change in their ICB classification.  
 
"As a result of ICB's recent sector evaluation, five securities will be added back into the Index as their sector classification has been changed to biotechnology or pharmaceutical," Nasdaq said on Friday. "In addition to qualifying for this sector, companies being added back met all other continued eligibility criteria."
 
The change will become effective on July 24.

The Scan

Could Mix It Up

The US Food and Drug Administration is considering a plan that would allow for the mixing-and-matching of SARS-CoV-2 vaccines and boosters, the New York Times says.

Closest to the Dog

New Scientist reports that extinct Japanese wolf appears to be the closest known wild relative of dogs.

Offer to Come Back

The Knoxville News Sentinel reports that the University of Tennessee is offering Anming Hu, a professor who was acquitted of charges that he hid ties to China, his position back.

PNAS Papers on Myeloid Differentiation MicroRNAs, Urinary Exosomes, Maize Domestication

In PNAS this week: role of microRNAs in myeloid differentiation, exosomes in urine, and more.